The Global Antibiotic Research and Development Partnership (GARDP) Not-For-Profit Model of Antibiotic Development


15 May 2020

Manica Balasegaram and Laura J. V. Piddock
ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.0c00101

Abstract

The Global Antibiotic Research and Development Partnership (GARDP) brings together public and private partners to accelerate the development and global availability of new antibiotics to treat the most challenging drug-resistant bacterial infections. Established in 2016, GARDP’s recently launched strategy sets out its ambitious aim to deliver five new treatments by 2025, focusing on sexually transmitted infections, sepsis in newborns, and infections in hospitalized adults and children.

Click here to read the article


We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.